期刊
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
卷 429, 期 3-4, 页码 148-155出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bbrc.2012.10.123
关键词
STEAP1; Gene expression profiling; Cancer
资金
- ARC (Paris France) [SL220110603450]
- European Community
- ANR emergence
- FEDER [141786, 42667]
- INCa-Canceropole GSO from the Hopp-Foundation, Germany [2012-011]
- University of Heidelberg, Germany
- National Centre for Tumor Diseases, Heidelberg, Germany
- Tumorzentrum Heidelberg/Mannheim, Germany
- Deutsche Krebshilfe, Bonn, Germany
- Deutsche Forschungsgemeinschaft, Bonn, Germany
The six-transmembrane epithelial antigen of prostate (STEAP) protein was identified in advanced prostate cancer and is up-regulated in multiple cancer cell lines, including prostate, bladder, colon, ovarian, and Ewing sarcoma. STEAP1 was described as a suitable antigen for T-cell-based or antibody-based immunotherapy. We have investigated the expression of STEAP1 in 40 human tumor types - brain, epithelial, lymphoid and in their normal tissue counterparts using publicly available gene expression data, including the Oncomine Cancer Microarray database. STEAP1 was found significantly overexpressed in 11 cancers. In addition, high STEAP1 expression was associated with poor overall survival in colorectal cancer, diffuse large B cell lymphoma, acute myeloid leukemia and multiple myeloma. Taken together, these data suggest that STEAP1 is a potential therapeutic target for T-cell based immunotherapy or antibody therapy in a large panel of cancers. (C) 2012 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据